Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint
February 25, 2020 4:16 PM ESTVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic dermatitis (AD) in adults. The EPIONE study did not meet its primary endpoint in reduction of pruritus across the overall study population. However, the antipruritic effect of tradipitant was robust in the mild AD study population. Mild AD represents over 60% of the total AD population in the U.S.1, 2 The EPIONE study continued to demonstrate that tradipitant is safe and well-tolerated.
"Although we are disappointed... More
Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 3c
February 25, 2020 4:03 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $60.9 million versus the consensus estimate of $59.57 million.
"We had another year of outstanding commercial growth," said Mihael H. Polymeropoulos,... More
Vanda Pharmaceuticals (VNDA) Halted, News Pending
February 25, 2020 4:03 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) Halted, News Pending
... More